Hideya Onishi, Takafumi Morisaki, Fumihiko Nakao, Seiichi Odate, Takashi Morisaki, Mitsuo Katano
Index: Cancer Lett. 335(2) , 289-98, (2013)
Full Text: HTML
To develop an effective therapeutic approach to pancreatic ductal adenocarcinoma (PDAC), we focused on the antitumor mechanism of protein-bound polysaccharide (PSK) under hypoxia. PSK decreased proliferation in PDAC cells under hypoxia but not normoxia. PSK also showed anti-tumor effects in vivo, inhibited invasiveness of PDAC cells, and decreased the expression of HIF-1α and hedgehog (Hh) signaling-related molecules under hypoxia. Inhibition of HIF-1α and Hh signaling reduced proliferation and invasiveness in PDAC cells under hypoxia. In conclusion, we found new PSK-related pathways in invasiveness and proliferation in PDAC under hypoxia. PSK may be a promising therapeutic drug to treat refractory PDAC.Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
α1-Acid Glycoprotein, from human plasma
CAS:66455-27-4 |
|
Biological mechanism and clinical effect of protein-bound po...
2012-01-01 [Surg. Today 42(1) , 8-28, (2012)] |
|
Direct inhibition of the transforming growth factor-β pathwa...
2012-02-01 [Cancer Sci. 103(2) , 317-24, (2012)] |
|
Immunotherapy eradicates metastases with reversible defects ...
2011-09-01 [Cancer Immunol. Immunother. 60(9) , 1257-68, (2011)] |
|
Polysaccharide-K (PSK) may suppress surgical stress-induced ...
2012-03-01 [Langenbecks. Arch. Surg. 397(3) , 475-80, (2012)] |
|
Polysaccharide-K augments docetaxel-induced tumor suppressio...
2012-04-01 [Int. J. Oncol. 40(4) , 905-13, (2012)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
